Navigate the Valsartan Recall
September 2018
The valsartan recall will continue to raise questions about how to switch to a different ARB or an ACE inhibitor.
The recalled products may have been contaminated with the probable carcinogen N-nitrosodimethylamine (NDMA) for as long as the past 4 years...possibly because of changes in how valsartan was made.
Reassure patients that cancer risk is very low. You can point out that about 8,000 patients would need to take the recalled valsartan 320 mg daily for 4 years to possibly lead to one additional lifetime diagnosis of cancer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive